|Table of Contents|

Changes and clinical significance of serum IL-2R,IL-6,IL-8,IL-10 and TNF-α in patients with non-Hodgkin' s lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 21
Page:
4025-4029
Research Field:
Publishing date:

Info

Title:
Changes and clinical significance of serum IL-2R,IL-6,IL-8,IL-10 and TNF-α in patients with non-Hodgkin' s lymphoma
Author(s):
LIU Jianping1; 2; LONG Yifei1; 2; CAI Yimei1; 2; MENG Shaowei1; 2; DI Ping3
1.The Second Affliated Hospital of Guangzhou University of Chinese Medicine,Guangdong Guangzhou 510000,China;2.Department of Laboratory Medicine,Guangdong Provincial Hospital of Chinese Medicine，Guangdong Guangzhou 510120，China;3.Department of Laboratory,the First Medical Center,General Hospital of Chinese PLA,Beijing 100853,China.
Keywords:
non-Hodgkin's lymphoma; IL-2R; IL-6; IL-8; IL-10; TNF-α
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.21.022
Abstract:
Objective:To explore the variation and clinical significance of IL-2R，IL-6，IL-8，IL-10，TNF-α serum levels in non-Hodgkin's lymphoma（NHL).Method:A total of 63 NHL patients admitted to the First Medical Center,General Hospital of Chinese PLA were collected and serum levels of IL-2R，IL-6，IL-8，IL-10，and TNF-α were restrospectively analyzed before and after treatment.Results：The serum levels of IL-2R，IL-6，and TNF-α were significantly increased in NHL patients with Ann Arbor stage Ⅲ-Ⅳ and IPI score≥3（P<0.05)，while IL-8 level was significantly increased in non-GCB subtypes and the patients with disease duration less than 5 years（P<0.05).The IL-10 level was significantly increased in patients with an IPI score of ≥3（P<0.05).During the treatment process，the levels IL-2R，IL-10，TNF-α in NHL patients who received CAR-T immunotherapy for 6 months with complete remission，chemotherapy，and targeted therapy were significantly higher than those in normal control group（P<0.05).Compared with the NHL standard classic first-line treatment regimen R-CHOP，the levels of IL-2R，TNF-α were significantly increased in CDP and MOAP treatment regimens，while IL-6 and IL-8 levels were only significantly increased in CDP treatment（P<0.05).After CAR-T immunotherapy，IL-2R levels>387 U/mL（P=0.006 7) and IL-8 levels>12 pg/mL（P=0.047) in NHL patients were significantly associated with recurrence.Conclusion:The levels of IL-2R，IL-6，IL-8，IL-10 and TNF-α were related to the occurrence，development，treatment，and prognosis of NHL，which may be effective serum markers for NHL.

References:

［1］VOORZANGER N，TOUITOU R，GARCIA E，et al.Interleukin（IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors［J］.Cancer Research，1996，56(23):5499-5505.
［2］PROPPER D，BALKWILL F.Harnessing cytokines and chemokines for cancer therapy［J］.Nat Rev Clin Oncol，2022，19(4):237-253.
［3］SWERDLOW S，CAMPO E，PILERI S，et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］.Blood，2016，127(20):2375-2390.
［4］CHESON B.The international harmonization project on lymphoma.Revised response criteria for malignant lymphoma［J］.Journal of Clinical Oncology，2007，25(5):579-586.
［5］GOH T，HONG C.New insights of common gamma chain in hematological malignancies［J］.Cytokine，2015，89(1):179-184.
［6］MASAYA I，EISEI K，KATSUYOSHI T，et al.Diagnosis of follicular lymphoma of the gastrointestinal tract:A better initial diagnostic workup［J］.World Journal of Gastroenterology，2016，22(4):1674-1683.
［7］MORITA-FUJITA M，KATOH D，SHIMOMURA Y，et al.High level of serum soluble interleukin-2 receptor is associated with poor survival in patients with first relapsed or refractory peripheral T-cell lymphoma，not otherwise specified:A retrospective study［J］.Clinical Lymphoma，Myeloma & Leukemia，2019，19(7):337-342.
［8］CHEN Z，YOU L，WANG L，et al.Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo［J］.Journal of Experimental & Clinical Cancer Research，2018，37(1):190-208.
［9］YOSUKE OHNO，YUJIRO TOYOSHIMA,HIDEAKI YURINO，et al.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy［J］.Cancer Science，2017，108(10):1959-1966.
［10］WANG L，ZHAO Y，QIAN J，et al.Toll-like receptor-4 signaling in mantle cell lymphoma effects on tumor growth and immune evasion［J］.Cancer，2013，119(4):782-791.
［11］TEKE HU，GULBAS Z，BAL C.Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value［J］.Journal of BUON，2014，19(1):191-197.
［12］HSI ED，LI HL，NIXON AB，et al.Serum levels of TARC，MDC，IL-10，and soluble CD163 in Hodgkin lymphoma:A SWOG S0816 correlative study［J］.Blood，2019，133(16):1762-1765.
［13］沈静，张永超，杨融辉，等.血清IL-6及IL-10在非霍奇金淋巴瘤患者血清中的表达及临床意义［J］.现代肿瘤医学，2022，30(6):1076-1079. SHEN J,ZHANG YC,YANG RH,et al.Expression and clinical significance of serum IL-6 and IL-10 in patients with non-Hodgkin's lymphoma［J］.Modern Oncology,2022,30(6):1076-1079.
［14］HIMENO T，WATANABE N，YAMAUCHI N，et al.Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor［J］.Cancer Research，1990，50(16):4941-4946.
［15］SUN L，WANG J，WANG Q，et al.Pretreatment of umbilical cord derived MSCs with IFN-γ and TNF-α enhances the tumor-suppressive effect on acute myeloid leukemia［J］.Biochemical Pharmacology，2022，199(5):115007.
［16］DLOUHY I，FILELLA X，ROVIRA J，et al.High serum levels of soluble interleukin-2 receptor（sIL2-R)，interleukin-6（IL-6) and tumor necrosis factor alpha（TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma［J］.Leukemia Research，2017，59(1):20-25.
［17］IBRAHIM A，RAHMAN HA，KHORSHIED M，et al.Tumor necrosis factor alpha-308 and lymphotoxin alpha+252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt［J］.Leukemia Research，2012，36(6):694-698.
［18］WARZOCHA K，RIBEIRO P，BIENVENU J，et al.Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome［J］.Blood，1998，91(10):3574-3581.
［19］WANG Y，ZHANG WY，HAN QW，et al.Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells［J］.Clin Immunol，2014，155(2):160-175.
［20］TURTLE CJ，BERGER C，SOMMERMEYER D，et al.Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia:Fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes［J］.Blood,2015，23(126):184-188.
［21］HAYDU J，ABRAMSON J.CAR T-cell therapies in lymphoma:Current landscape，ongoing investigations，and future directions［J］.Journal of Cancer Metastasis and Treatment，2021，36(7):1-14.
［22］李晓瑞,尚凤琴,王建勋.CAR-T疗法在治疗肿瘤免疫逃逸中的研究进展［J］.现代肿瘤医学，2021,29（15）：2735-2738. LI XR,SHANG FQ,WANG JX.The research progress of CAR-T therapy in the treatment of tumor immune escape［J］.Modern Oncology，2021,29（15）：2735-2738.

Memo

Memo:
-
Last Update: 2023-09-28